Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
University Hospital Muenster
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
65High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02845882CT.gov LBL-2016 for Children or Adolescents in China | — | Active Not Recruiting | — | — | — |
NCT02393157CT.gov Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | — | Recruiting | — | — | — |
NCT00601718CT.gov Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT00199082CT.gov Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lymphoblastic Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Isocyclophosphamide (this asset) | University Hospital Muenster | Approved | BB · 68 |
| Rituximab | University of Washington | P4 | BBB |
| Cladribine | Fifth Affiliated Hospital, Sun Yat-Sen University | P4 | BBB |
| Etoposide | University of Washington | P4 | BBB |
| Pegaspargase | Chongqing Peg-Bio Biopharm Co., Ltd. | P4 | BBB |
| Mercaptopurine Anhydrous | City of Hope Medical Center | P4 | BBB |
| Vindesine | University Hospital Muenster | P4 | BBB |
| Methotrexate | City of Hope Medical Center | P4 | BB |
| Thioguanine Anhydrous | St. Jude Children's Research Hospital | P4 | BB |
+42 more in the Lymphoblastic Lymphoma cohort
Other indications for Isocyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Angioimmunoblastic T-Cell Lymphoma | — | P4 | BBB · 76 |
| Primary Mediastinal Large B-Cell Lymphoma | — | P4 | BBB · 76 |
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Isocyclophosphamide in Lymphoblastic Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/isocyclophosphamide-lymphoblastic-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →